Literature DB >> 10160483

Health impact of influenza in the United States.

K M Sullivan1.   

Abstract

Influenza infection is associated with significant morbidity and mortality. The purpose of this investigation was to describe the health effects of influenza in the US. Although a number of different data sources have been used to provide estimates of the health impact of influenza in the US, estimates provided in this article are primarily based upon the experiences reported in community-based studies performed in Houston, Texas, and Tecumseh, Michigan. Estimates of the annual average are provided for the following: (1) infection rate; (2) number of influenza-associated respiratory illnesses; (3) number of ill days with influenza; (4) number of bed and activity restriction days due to influenza illness; (5) physician visits; (6) hospitalisations and days hospitalised; and (7) mortality. Large differences were found between estimates from Houston and Tecumseh, and possible explanations for these are provided. However, all estimates find that influenza is an important cause of morbidity and mortality in the US.

Entities:  

Mesh:

Year:  1996        PMID: 10160483     DOI: 10.2165/00019053-199600093-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  8 in total

1.  Methods for current statistical analysis of excess pneumonia-influenza deaths.

Authors:  Robert E Serfling
Journal:  Public Health Rep       Date:  1963-06       Impact factor: 2.792

2.  The Tecumseh study of respiratory illness. 3. Incidence and periodicity of respiratory syncytial virus and Mycoplasma pneumoniae infections.

Authors:  A S Monto; S K Lim
Journal:  Am J Epidemiol       Date:  1971-09       Impact factor: 4.897

3.  Estimates of the US health impact of influenza.

Authors:  K M Sullivan; A S Monto; I M Longini
Journal:  Am J Public Health       Date:  1993-12       Impact factor: 9.308

Review 4.  Serious morbidity and mortality associated with influenza epidemics.

Authors:  W P Glezen
Journal:  Epidemiol Rev       Date:  1982       Impact factor: 6.222

5.  Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981.

Authors:  A S Monto; J S Koopman; I M Longini
Journal:  Am J Epidemiol       Date:  1985-06       Impact factor: 4.897

6.  Acute respiratory illness in the community. Frequency of illness and the agents involved.

Authors:  A S Monto; K M Sullivan
Journal:  Epidemiol Infect       Date:  1993-02       Impact factor: 2.451

7.  The Tecumseh study of respiratory illness. I. Plan of study and observations on syndromes of acute respiratory disease.

Authors:  A S Monto; J A Napier; H L Metzner
Journal:  Am J Epidemiol       Date:  1971-09       Impact factor: 4.897

8.  Prevention and control of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1995-04-21
  8 in total
  10 in total

1.  Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company.

Authors:  E Burckel; T Ashraf; J P de Sousa Filho; E Forleo Neto; H Guarino; C Yauti; B Barreto F de; L Champion
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

2.  A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK.

Authors:  Roben Das Gupta; Julian F Guest
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  Influenza. The role of burden-of-illness research.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

Review 4.  Antivirals for influenza: strategies for use in pediatrics.

Authors:  Steven M Smith; John G Gums
Journal:  Paediatr Drugs       Date:  2010-10-01       Impact factor: 3.022

5.  A study of influenza and influenza-related complications among children in a large US health insurance plan database.

Authors:  Jeanne Loughlin; Nick Poulios; Pavel Napalkov; Yann Wegmüller; Arnold S Monto
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 6.  Role of influenza vaccine for healthy children in the US.

Authors:  Stan L Block
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

7.  Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza A virus.

Authors:  Gabriel L Hendricks; Kim L Weirich; Karthik Viswanathan; Jing Li; Zachary H Shriver; Joseph Ashour; Hidde L Ploegh; Evelyn A Kurt-Jones; Deborah K Fygenson; Robert W Finberg; James C Comolli; Jennifer P Wang
Journal:  J Biol Chem       Date:  2013-01-28       Impact factor: 5.157

8.  Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects.

Authors:  R Gasparini; T Pozzi; E Montomoli; E Fragapane; F Senatore; M Minutello; A Podda
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 12.434

9.  Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial.

Authors:  Kyuri Kang; Seunghoon Han; Taegon Hong; Sangil Jeon; Jeongki Paek; Jin Han Kang; Dong Seok Yim
Journal:  Yonsei Med J       Date:  2016-11       Impact factor: 2.759

10.  Operational issues and network effects in vaccine markets.

Authors:  Elodie Adida; Debabrata Dey; Hamed Mamani
Journal:  Eur J Oper Res       Date:  2013-05-31       Impact factor: 5.334

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.